Zanidatamab Redefines First-Line Therapy in HER2-Positive Upper GI Malignancies

15 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
Join the Oncology Brothers, Rahul and Rahul Gosain, as they delve into the rapidly evolving landscape of upper gastrointestinal (GI) cancer treatment in this insightful podcast episode. In this clinical insight segment, they discuss the latest data from the Horizon GEA-01 study, featuring the promising bispecific antibody Zanidatamab, and its implications for HER2-positive metastatic gastroesophageal junction and gastric adenocarcinoma.
In this episode, you'll hear from an expert panel, including Dr. Nataliya Uboha from the University of Wisconsin, Dr. Jeffrey Kuh from MSK, Dr. Rutika Mehta, and Dr. Manish from Weill Cornell. They explore:
• The current standard of care for HER2-positive metastatic gastric cancer
• The mechanism of action of Zanidatamab and its unique dual binding capabilities
• Key findings from the Horizon GEA-01 study, including comparisons of Zanidatamab with traditional treatments
• Insights into the significance of PD-L1 status in treatment decisions
Tune in for a comprehensive discussion on the future of GI cancer therapies and the exciting developments that could change patient outcomes.

Website: https://oncupdates.com/
Mail: [email protected]
X/twitter: https://x.com/OncUpdates

Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!
#gastriccancer , #HER2positive, #Zanidatamab, #HORIZONGEA01, #OncologyBrothers
Categoria
Oncology
Commenta per primo questo video.

Prossimo